Sharp Shalini
SEC-identified person · CIK 1377202 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Septerna, Inc. SEPN | Director | filed 2024 - 2026 |
| Beigene, Ltd. ONC | Director | filed 2024 - 2026 |
| Organon & Co. ORG | Director | filed 2021 - 2026 |
| Neurocrine Biosciences INC NBIX | Director | filed 2020 - 2026 |
| Mirati Therapeutics, Inc. mrtx | Director | filed 2021 - 2024 |
| Sutro Biopharma, INC. STRO | Director | filed 2018 - 2022 |
| Precision Biosciences INC DTIL | Director | filed 2019 - 2021 |
| Panacea Acquisition Corp PANA | Director | filed 2020 - 2021 |
| Ultragenyx Pharmaceutical Inc. RARE | See Remarks | filed 2014 - 2020 |
| Array Biopharma INC ARRY | Director | filed 2017 - 2019 |
| Antigenics INC /DE/ agend | Director · CFO | filed 2006 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.